HRC 201

Drug Profile

HRC 201

Alternative Names: HRC-201

Latest Information Update: 05 Sep 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hemosol Corp
  • Developer Hemosol Corp (CEASED)
  • Class Haemoglobins; Radiopharmaceutical diagnostics
  • Mechanism of Action Magnetic resonance imaging enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Liver metastases

Most Recent Events

  • 02 Feb 2004 HCR 201 is available for licensing (http://www.hrc.hemosol.com)
  • 02 Feb 2004 Preclinical trials in Liver metastases (diagnosis) in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top